Live Breaking News & Updates on Global Medicine Development

Stay updated with breaking news from Global medicine development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Paul Beresford , Caroline Germa , Los Angeles , Product Development Center , Clinical Development Centers , Transcenta Holding , Transcenta Immune Tolerance Breaking Technology , Global Medicine Development , Prnewswire Transcenta Holding Limited , Translational Research Center , Group Headquarters , Agilent Technologies , Holding Limited , Investigational Use , Performance Evaluation Only , Executive Vice President , Chief Medical , Immune Tolerance Breaking Technology , Orphan Drug Designation , Manufacturing Facility , External Partnering Center , Suzhou Industrial ,

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , France General , Rebecca Cohen , Mark Manfredi , Luke Shiplo , Caroline Germa , Sergio Santillana , Paris Diderot University , Exchange Commission , Lifesci Communications , Bristol Myers Squibb As Development Team , Global Medicine Development , Head Of Oncology Early Development Clinical Group , University Of Lille , Ikena Oncology Inc , Oncology Appoints Caroline Germa , Chief Medical , Chief Medical Officer , Chief Executive Officer , Transcenta Therapeutics , Vice President , Oncology Early Development Clinical Group , Bristol Myers Squibb , Development Team Lead , Medical Doctor , Private Securities Litigation Reform Act ,

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France General , United States , Luke Shiplo , Mark Manfredi , Sergio Santillana , Rebecca Cohen , Caroline Germa , Paris Diderot University , Global Medicine Development , Ikena Oncology Inc , Bristol Myers Squibb As Development Team , Lifesci Communications , Exchange Commission , University Of Lille , Head Of Oncology Early Development Clinical Group , Oncology Appoints Caroline Germa , Chief Medical , Chief Medical Officer , Chief Executive Officer , Transcenta Therapeutics , Vice President , Oncology Early Development Clinical Group , Bristol Myers Squibb , Development Team Lead , Medical Doctor , Private Securities Litigation Reform Act ,

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise ....

United States , France General , Sergio Santillana , Caroline Germa , Mark Manfredi , Luke Shiplo , Rebecca Cohen , University Of Lille , Bristol Myers Squibb As Development Team , Ikena Oncology Inc , Paris Diderot University , Lifesci Communications , Global Medicine Development , Head Of Oncology Early Development Clinical Group , Exchange Commission , Chief Medical , Chief Executive Officer , Chief Medical Officer , Transcenta Therapeutics , Vice President , Oncology Early Development Clinical Group , Bristol Myers Squibb , Development Team Lead , Medical Doctor , Private Securities Litigation Reform Act , Quarterly Report ,

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all ....

United States , Caroline Germa , Los Angeles , Transcenta Holding , Transcenta Immune Tolerance Breaking Technology , Transcenta Holding Limited , Clinical Development Centers In Princeton , Translational Research Center , Product Development Center , Global Medicine Development , Group Headquarters , Executive Vice President , Chief Medical , Manageable Safety , Immune Tolerance Breaking Technology , Orphan Drug Designation , Manufacturing Facility , Clinical Development Centers , External Partnering Center , Suzhou Industrial ,